Prediction of hospital outcome in septic shock: a prospective comparison of tissue Doppler and cardiac biomarkers by Sturgess, David J et al.
RESEARCH Open Access
Prediction of hospital outcome in septic shock: a
prospective comparison of tissue Doppler and
cardiac biomarkers
David J Sturgess
1,2*, Thomas H Marwick
1,3, Chris Joyce
1,4, Carly Jenkins
1,3, Mark Jones
5, Paul Masci
1, David Stewart
4,
Bala Venkatesh
1,2,4
Abstract
Introduction: Diastolic dysfunction as demonstrated by tissue Doppler imaging (TDI), particularly E/e’ (peak early
diastolic transmitral/peak early diastolic mitral annular velocity) is common in critical illness. In septic shock, the
prognostic value of TDI is undefined. This study sought to evaluate and compare the prognostic significance of TDI
and cardiac biomarkers (B-type natriuretic peptide (BNP); N-terminal proBNP (NTproBNP); troponin T (TnT)) in septic
shock. The contribution of fluid management and diastolic dysfunction to elevation of BNP was also evaluated.
Methods: Twenty-one consecutive adult patients from a multidisciplinary intensive care unit underwent
transthoracic echocardiography and blood collection within 72 hours of developing septic shock.
Results: Mean ± SD APACHE III score was 80.1 ± 23.8. Hospital mortality was 29%. E/e’ was significantly higher in
hospital non-survivors (15.32 ± 2.74, survivors 9.05 ± 2.75; P = 0.0002). Area under ROC curves were E/e’ 0.94, TnT
0.86, BNP 0.78 and NTproBNP 0.67. An E/e’ threshold of 14.5 offered 100% sensitivity and 83% specificity.
Adjustment for APACHE III, cardiac disease, fluid balance and grade of diastolic function, demonstrated E/e’ as an
independent predictor of hospital mortality (P = 0.019). Multiple linear regression incorporating APACHE III, gender,
cardiac disease, fluid balance, noradrenaline dose, C reactive protein, ejection fraction and diastolic dysfunction
yielded APACHE III (P = 0.033), fluid balance (P = 0.001) and diastolic dysfunction (P = 0.009) as independent
predictors of BNP concentration.
Conclusions: E/e’ is an independent predictor of hospital survival in septic shock. It offers better discrimination
between survivors and non-survivors than cardiac biomarkers. Fluid balance and diastolic dysfunction were
independent predictors of BNP concentration in septic shock.
Introduction
Septic shock in adults refers to a state of acute circula-
tory failure characterized by persistent arterial hypoten-
sion unexplained by other causes [1]. Although this
clinical syndrome is heterogeneous with regard to fac-
tors such as causal micro-organism, patient predisposi-
tion, co-morbidity and response to therapy, a key
element and unifying feature is the manifestation of car-
diovascular dysfunction. Although the underlying cause
of death in septic shock is often multifactorial, refractory
hypotension and cardiovascular collapse are frequently
observed in the terminal phases of the condition [2].
Whilst impaired systolic function has been identified as
the major culprit, the contribution of diastolic dysfunc-
tion (and hence ventricular filling) to cardiovascular
morbidity and mortality in septic shock is not fully
understood. Investigation of left ventricular (LV) diasto-
lic function at the bedside is challenging, but techniques
such as echocardiography and biomarkers such as
B-type natriuretic peptide (BNP) are increasingly sup-
ported by current literature [3-5]. In particular, recent
application of non-invasive, bedside technologies, such
as tissue Doppler imaging (TDI), offer fresh insight [6].
TDI is an echocardiographic technique that measures
myocardial velocities [7], which are low frequency,
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pler imaging [8]. TDI has gained acceptance amongst
cardiologists for the evaluation of diastolic function,
particularly as a measure of ventricular relaxation and
ventricular filling pressure [9]. However, there are
scant data regarding its use in critical care. TDI has
demonstrated prognostic utility in a range of cardio-
vascular diseases [10], including following myocardial
infarction [11,12], heart failure [13-16], abnormal LV
function at dobutamine echocardiography [17], non-
valvular atrial fibrillation [18], hypertension [19], and
end-stage renal disease [20].
Previously, we demonstrated that evidence of diastolic
dysfunction on TDI is common in critically ill patients
[21]. The significance of this was recently highlighted by
Ikonomidis and colleagues, who demonstrated that TDI
may be prognostically useful in the general ICU popula-
tion [22]. To date, the prognostic significance of this
technique has not been specifically evaluated in septic
shock.
Cardiac biomarkers including BNP [23,24], N-terminal
proBNP (NTproBNP) [25] and troponin [26] potentially
offer prognostic information in the critically ill. To date,
no comparison has been made between TDI and cardiac
biomarkers (BNP, NTproBNP and troponin) with regard
to prediction of hospital outcome in septic shock.
This study sought to evaluate and compare the prog-
nostic significance of TDI variables and cardiac biomar-
kers in septic shock. An auxiliary aim was to evaluate
the potential contribution of LV diastolic dysfunction
and fluid management to elevation of plasma BNP con-
centrations in septic shock.
Materials and methods
This prospective observational study was approved by
the Princess Alexandra Hospital Human Research Ethics
Committee (project 2005/213), and the Guardianship
and Administration Tribunal of Queensland (project
2006/07) and informed consent was obtained from the
patient or legally authorized representative where
appropriate.
Patients
Twenty-one consecutive adult patients with septic shock
were recruited from the ICU during an 11-month period
(May 2005 to March 2006). Eligible patients were
enrolled within 72 hours of admission to the ICU with
septic shock or development of septic shock while in
the ICU. Septic shock was defined as severe sepsis with
persistent hypotension (ie. with a mean arterial pressure
(MAP) < 60 mmHg or a reduction in systolic blood
pressure (SBP) > 40 mmHg from baseline) despite ade-
quate volume resuscitation in the absence of other
causes for hypotension [1].
Exclusion criteria included: age younger than 18 years;
presence of moderate to severe valvular heart disease; or
patient or legally authorized representative declined
participation.
Patient care followed standard practice. Clinical fluid
resuscitation and management were undertaken in a
fashion consistent with surviving sepsis guidelines [27].
More specifically, fluid challenges were undertaken
incrementally while clinical response was observed.
Therapeutic variables considered in determining the
requirement and response to fluid management
included pulse rate, blood pressure (target MAP >
65 mmHg), peripheral perfusion, urine output (target >
0.5 ml/kg/hr), and central venous pressure (CVP).
Research measurements were not released to the treat-
ing clinician.
Clinical and outcome data
Clinical data included height,w e i g h t ,v e n t i l a t i o nm o d e
and settings, heart rate, rhythm, arterial blood pressure
(SBP; diastolic blood pressure (DBP); MAP) and CVP.
Body surface area (BSA) was calculated [28]. ICU fluid
balance was recorded for the study day (fluid balance).
Vasopressor/inotropic infusion rates and, ICU and hos-
pital length of stay and outcome were recorded. Illness
severity was quantified using (Acute Physiology and
Chronic Health Evaluation) APACHE III and Sequential
Organ Failure Assessment (SOFA) scores. Patients were
considered to have a history of cardiac disease if they
had prior or current ischemic heart disease (angina or
myocardial infarction) or cardiac surgery.
Echocardiography
Transthoracic echocardiography and Doppler examina-
tions were performed by experienced echocardiogra-
phers (coordinated by Jenkins C) using commercially
available echocardiographic equipment (Acuson Sequoia,
Siemens AG, Munich, Germany and Sonos 7500, Philips
Medical Systems, Andover, MA, USA). Measurements
were made off-line, using AccessPoint™ 2000 software
(Freeland Systems, Westfield, IN, USA). Unless other-
wise stated, measurements were made in triplicate at
end expiration.
Two-dimensional echocardiography
LV end-diastolic volume (LVEDV) and LV end-systolic
volume (LVESV) were calculated using the biplane
method of disks (modified Simpson’s rule) from the api-
cal four-chamber and two-chamber views [29] and
indexed to BSA (LVEDVI and LVESVI, respectively). LV
ejection fraction (LVEF) was calculated as (LVEDV -
LVESV)/LVEDV × 100. Systolic dysfunction was defined
as EF below 55%. LV outflow tract diameter (OTD) was
recorded as the maximum measurement from triplicate
zoomed parasternal long axis view.
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Transmitral flow velocities were recorded with pulsed-
wave Doppler with the sample volume placed at the
mitral valve tips from the apical four-chamber view [30].
Peak passive (E) and active (A) velocities were recorded.
E wave deceleration time (DT) was measured. E to A
ratio (E/A) was calculated.
Doppler interrogation of LV outflow tract velocity was
guided by apical five-chamber view [30]. Heart rate
(HR), velocity time integral (VTI) and peak velocity
(Vpeak) were measured. Stroke volume was calculated
as the product of VTI and cross-sectional area of the
LV outflow tract [π.(OTD/2)
2]. Cardiac output was cal-
culated as the product of stroke volume and HR. Stroke
volume and cardiac output measurements were indexed
to body surface area (SVI and CI, respectively).
Tissue Doppler
Myocardial velocities were obtained using tissue Doppler
settings, with the pulsed-wave Doppler sample volume at
the septal mitral annulus in the apical four-chamber view.
Peak systolic (s’), early diastolic (e’) and late diastolic (a’)
myocardial velocities were measured. E/e’ was calculated.
When A and/or a’ were indistinguishable due to sinus
tachycardia, E and/or e’ were measured as described by
Nagueh and colleagues [31]. In the presence of atrial
dysrhythmia, transmitral and tissue Doppler velocities
were measured over five consecutive cardiac cycles [18].
As previously described [21], thresholds for abnormal
diastolic TDI were accepted as e’less than 9.6 cm/s
(myocardial relaxation below the lower 95% confidence
limit of normal subjects) [32] or E/e’ more than 15
(mean LV end-diastolic pressure > 15 mmHg) [33].
Diastolic dysfunction
Guidelines previously published by our group were used to
grade LV diastolic function as normal, impaired relaxation,
pseudonormal or restrictive [34]. Age-dependent thresh-
olds for deceleration time (< 40 years < 220 ms; 40 to 60
years 140 to 250 ms; > 60 years 140 to 275 ms) were used
to determine impaired relaxation (DT above normal limit)
and restrictive patterns (DT below normal limit). In order
to distinguish between normal and pseudonormal pat-
terns, we incorporated E/e’ (normal < 8; pseudonormal >
15). Where E/e’ was inconclusive (8 to 15), increased left
atrial area (> 20 cm) was used as a marker of raised LV
filling pressure (pseudonormal pattern). Patients categor-
ized other than normal were considered to have diastolic
dysfunction.
Biochemical assay
Plasma BNP concentration was measured using a Biosite
Triage® immunoassay (Biosite Diagnostics, San Diego,
CA, USA), Plasma Troponin T (TnT; Elecsys® Troponin
T, 3
rd generation immunoassay; Roche Diagnostics Aus-
tralia Pty Ltd, Castle Hill, NSW, Australia) and
NTProBNP concentration (Elecsys® proBNP, Roche
Diagnostics Australia Pty Ltd, Castle Hill, NSW, Austra-
lia) were run on Roche Elecsys® analyzers (Roche Diag-
nostics Australia Pty Ltd, Castle Hill, NSW, Australia).
Plasma C reactive protein (CRP) concentration was
measured using an immunotubidometric assay (UniCel®
DxI 800 Access® Immunoassay System, Beckman Coul-
ter Australia Pty. Ltd., Gladesville, NSW, Australia).
Laboratory thresholds were used to determine elevation
of biomarkers: BNP (normal < 100 ng/L), NTproBNP (0
to 50 years < 450; 50 to 75 years < 900; > 75 years <
1800 ng/L), TnT (< 0.03 μg/L) and CRP (< 5.0 mg/L).
Blinding
Coded echocardiographic and Doppler recordings were
analyzed at least one month after acquisition by a single
observer blinded to clinical and biochemical data.
Biochemical assay was performed on coded samples by
technicians blinded to clinical and echocardiographic data.
Statistics
Analysis was performed by SPSS, version 14.0 for Win-
dows (SPSS Inc., Chicago, IL, USA). Descriptive mea-
sures were used to evaluate the distribution of variables.
Differences between groups were assessed using Fisher’s
exact test for categorical data. Continuous data were
assessed using Levene’s test for equality of variance
before applying Student’s t-test for independent samples.
BNP and NTproBNP concentrations were log-trans-
formed to achieve normality before application of linear
regression techniques. Discrimination between hospital
survivors and non-survivors was evaluated by receiver
operating characteristic (ROC) curve analysis.
Cox proportional hazards regression was used for time
to event outcomes (hospital survival) from the time of
echocardiography. Adjustment was made for the poten-
tial influence of cardiac disease, fluid balance and grade
of diastolic dysfunction upon E/e’.
Multiple-linear regression analyses were undertaken to
determine contributions to BNP concentration (lnBNP).
Potential predictor variables included APACHE III score
(first ICU day), gender, [35], cardiac disease [35], intrave-
nous fluid therapy [36], noradrenaline dose [37], CRP [38],
LVEF [39], and LV diastolic dysfunction [40]. A backwards
elimination procedure was then used to discard predictor
variables with P < 0.1 in multiple regression models one
by one until a final ‘best’ model was achieved.
In final analyses, a P-value less than 0.05 was regarded
as significant. Unless stated otherwise, results are
reported as mean ± standard deviation (SD) (range).
Sample size
Subgroup analysis of septic patients from data previously
published by our group yielded a mean ± SD E/e’ of
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30% [21]. It was determined that a sample of 20 patients
would allow detection of a mean difference in E/e’ of 4
or more between survivors and non-survivors (80%
power; a = 0.05) [41].
Results
Patient characteristics
Twenty-one consecutive septic shock patients were stu-
died (Table 1). Fifteen participants (71%) were studied
within 24 hours of developing septic shock. Variables
recorded on the study day are presented in Table 2.
Sixteen patients (76%) were mechanically ventilated at
the time of the initial assessment. The requirement for
mechanical ventilation did not distinguish survivors
from non-survivors (P = 0.15). Of the mechanically ven-
tilated patients, positive end-expiratory pressure (PEEP)
requirements were not different between survivors and
non-survivors (7.05 ± 3 cmH2Ov s7 . 9±5 . 1c m H 2O,
respectively; P = 0.67).
Eleven patients (52%) were in normal sinus rhythm
and two (9.5%) were paced. Noradrenaline infusion was
running at the time of initial assessment in seventeen
patients (81%; Mean ± SD infusion rate 0.124 ± 0.12
micrograms/kg/min). In addition to noradrenaline, one
patient was receiving adrenaline and one was receiving
dopamine. Mean ± SD fluid balance on the day of study
was 1780 ± 1848 mL (range: -1734 to 5320).
The diagnosis of cardiac disease (Table 1) was based
on previous history (non-acute) in seven out of nine
patients. Of the remaining patients, one developed sepsis
secondary to wound infection eight days following aortic
root and valve replacement (no significant coronary
artery disease; survived to hospital discharge), whereas
the other developed pneumonia sixteen days following
emergency coronary artery bypass grafting for acute
myocardial infarction (non-survivor). No patients had a
previous history of heart failure. Fourteen patients had
been receiving treatment for hypertension prior to the
development of septic shock. Six patients had been pre-
viously diagnosed with diabetes mellitus (n = 5; all type
2) or glucose intolerance prior to the development of
septic shock.
Table 1 Patient characteristics
Total number of patients 21
Male:Female ratio 13:8
Age, years 65 ± 17 (24-86)
Height, cm 167 ± 7 (156-180)
Weight, kg 80 ± 18 (42-130)
Body surface area, m
2 1.88 ± 0.25 (1.4-2.5)
APACHE III score (Day 1 ICU) 80.1 ± 23.8 (46-141)
SOFA score (Day 1 ICU) 11 ± 2.8 (6-16)
ICU length of stay, days 12.5 ± 12.3 (1-54)
Hospital length of stay, days 29.6 ± 29.3 (1-125)
ICU mortality, n (%) 4 (19%)
Hospital mortality, n (%) 6 (29%)
28-day mortality, n (%) 6 (29%)
Source of infection
Abdominal, n (%) 8 (38%)
Pulmonary, n (%) 7 (33%)
Neurologic, n (%) 2 (9.5%)
Necrotizing fasciitis, n (%) 2 (9.5%)
Catheter related sepsis, n (%) 1 (5%)
Mediastinitis, n (%) 1 (5%)
Cardiac disease, n (%) 9 (43%)
Angina, n (%) 3 (14%)
Myocardial infarction, n (%) 6 (28%)
Cardiac surgery, n (%) 5 (24%)
APACHE, Acute Physiology and Chronic Health Evaluation; SOFA, Sequential
Organ Failure Assessment.
Table 2 Variables measured on study day
Variable Mean ± SD (Range)
Day of study
APACHE III score 82.9 ± 29.6 (28-141)
SOFA score 11.6 ± 3.6 (5-19)
Echocardiography
LVEDVI, mL/m
2 65.8 ± 22.4 (31.9-121.8)
LVESVI, mL/m
2 37.5 ± 18.5 (13.9-83.2)
SVI, mL/m
2 26.6 ± 14.5 (8.3-67.9)
EF, % 43 ± 14 (11-63)
VTI, cm 19.08 ± 5.06 (12.7-29.3)
Vpeak, m/s 1.042 ± 0.234 (0.71-1.48)
CI, L/min/m
2 3.14 ± 1.16 (1.9-6.32)
E, m/s 0.94 ± 0.27 (0.54-1.5)
DT, s 0.201 ± 0.054 (0.097-0.311)
A, m/s 0.63 ± 0.22 (0.22-1.17)
E/A 1.7 ± 1.1 (0.7-5.3)
e’, cm/s 9.3 ± 3.4 (4.8-18.8)
a’, cm/s 9.9 ± 3.3 (5.3-17.7)
E/e’ 10.93 ± 3.98 (4.29-18.56)
s’, cm/s 11.7 ± 4.2 (4.3-18.4)
Biochemistry
BNP, ng/L 714 ± 882 (49-2930)
NTproBNP, ng/L 1115 ± 1234 (28-4139)
CRP, mg/L 223 ± 96 (11-394)
TnT, μg/L 0.158 ± 0.21 (0-0.71)
a’, peak active (late) diastolic septal mitral annulus velocity; A, peak active
(late) diastolic transmitral flow velocity; APACHE, Acute Physiology and
Chronic Health Evaluation; BNP, B-type natriuretic peptide; CI, cardiac output
index; CRP, C reactive protein; DT, E wave deceleration time; e’, peak early
diastolic septal mitral annulus velocity; E, peak early diastolic transmitral flow
velocity; E/A, ratio of E to A; E/e’, ratio of E to e’; EF, ejection fraction; LVEDVI,
left ventricular end-diastolic volume index; LVESVI, left ventricular end-systolic
volume index; NTproBNP, N-terminal proBNP; s’, peak systolic septal mitral
annulus velocity; SD, standard deviation; SOFA, Sequential Organ Failure
Assessment; SVI, stroke volume index; TnT, troponin T; Vpeak, peak left
ventricular outflow tract velocity; VTI, left ventricular outflow tract velocity
time integral.
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Systolic dysfunction (EF < 55%) was evident in 14
patients (67%). Transthoracic measurement of e’ and E/
e’ was feasible in 20 of 21 patients. Fusion of E and A
waves was observed in four examinations (19%). Fusion
of e’and a’ waves was observed in three (15%). At initial
assessment, e’ was less than 9.6 cm/s in 11 (55%)
patients. At this time, E/e’ w a sm o r et h a n1 5i nt h r e e
(15%), 8 to 15 in thirteen (65%) and less than 8 in four
(20%) patients. TDI variables (including e’,a ’,s ’ and E/
e’) were not significantly different between ventilated
and non-ventilated patients. Diastolic function was
graded as normal in nine (43%), impaired relaxation in
three (14%), pseudonormal in seven (33%) and restric-
tive in two patients (10%). Thus, diastolic dysfunction
was present in 57% of patients (n = 12).
Biochemistry
BNP was elevated in fifteen patients (71%), NTproBNP
in six (28%) and TnT in fourteen (67%).
Hospital outcome
Significant differences were observed between hospital
survivors and non-survivors (Table 3) with respect to
E/e’ (survivor 9.05 ± 2.75, non-survivor 15.32 ± 2.74; P
=0 . 0 0 0 2 ) ,e ’ (survivor 10.4 ± 3.4 cm/s, non-survivor 6.8
±1 . 9c m / s ;P = 0.025) and s’ (survivor 13 ± 3.7 cm/s,
n o n - s u r v i v o r8 . 6±4 . 1c m / s ;P = 0.03). The area under
the ROC curve (c statistic) for each of these variables
was 0.94 for E/e’, 0.86 for e’and 0.83 for s’.A nE / e ’
threshold value of 14.5 offered sensitivity of 100% and
specificity of 83% (Figure 1). The c statistic of 0.86 for
TnT, 0.78 for BNP and 0.67 for NTproBNP. No differ-
ence in LVEF (systolic function) was observed (survivor
43 ± 15%, non-survivor 43 ± 14%; P = 0.91).
Prediction of hospital survival
Univariate Cox regression analysis (Table 3) yielded sig-
nificant associations between survival to hospital dis-
charge and E/e’ (P = 0.005), e’ (P = 0.04), s’ (P = 0.048)
and TnT (P = 0.03). Adjustment for APACHE III score,
history of cardiac disease, fluid balance and grade of dia-
stolic function, revealed E/e’ as an independent predic-
tor of hospital mortality (P = 0.019). A Kaplan-Meier
plot of the association between E/e’ and survival to hos-
pital discharge is shown in Figure 2.
Plasma BNP concentration
From an initial model containing APACHE III score,
gender, cardiac disease, fluid balance, noradrenaline dose,
CRP, EF and diastolic dysfunction, the backward elimina-
tion procedure yielded a ‘best’ model containing gender
(P = 0.089), APACHE III score (P = 0.033), fluid balance
(P = 0.001) and diastolic dysfunction (P = 0.009). This
final model accounted for 71.3% of variation in lnBNP
concentration (adjusted R square 0.713).
Discussion
The cardinal finding of this study is that E/e’ offers
independent and better prognostic prediction of hospital
outcome in septic shock as compared with cardiac bio-
markers (BNP, NTproBNP, TnT). We also observed
that conventional measures of systolic function, such as
EF and SVI (Table 3) did not discriminate between hos-
pital survivors and non-survivors. This study also
demonstrates that fluid balance and diastolic dysfunc-
tion are independent predictors of BNP concentration in
septic shock patients.
Diastolic function and tissue Doppler imaging in
septic shock
We have demonstrated an association between TDI
indices of diastolic function and outcome in septic shock.
The significance of this important new finding is high-
lighted by the superiority of these variables over the mea-
sures of cardiac systolic function and cardiac biomarkers
incorporated into this study. Despite demonstrating value
in a range of cardiovascular diseases [42], and more
recently in a study of general ICU patients by Ikonomidis
and colleagues [22], the prognostic potential of TDI in
septic shock per se has not previously been reported.
Our demonstration of an association between diastolic
function and mortality in septic shock complements
previous data. In a radionuclide cineangiographic study,
Parker and colleagues documented that non-survivors
did not demonstrate LV dilation (’preload adaptation’)
and therefore were unable to maintain stroke volume
and cardiac output [43,44]. Also, Munt and colleagues
demonstrated DT as an independent predictor of mor-
tality in severe sepsis [45]. In addition to our TDI find-
ings, we observed a trend toward an association
between DT and hospital mortality (P = 0.07). Although
no clear functional relation has been demonstrated, sep-
sis-induced diastolic dysfunction is likely to be asso-
ciated with a range of histologic abnormalities such as
inflammatory infiltrate, interstitial edema, apoptosis, and
necrosis [46,47].
The peak early diastolic mitral annular velocity (E)’,a s
measured by TDI, reflects LV relaxation [48,49].
Although this variable appears not to be as preload
insensitive as originally proposed [49,50], it is increas-
ingly valued as a quantitative index of LV diastolic func-
t i o n .T h i si sb e c a u s ei td o e snot pseudo-normalize in
the same way as transmitral flow [51]. Also, the E/e’
ratio has been proposed as an estimate of LV filling
pressure that corrects E velocity for the influence of
myocardial relaxation [33,52].
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Variable Survivors (Mean ± SD) Non-survivors (Mean ± SD) P* Cox Regression§
Baseline characteristics
n (%) 15 (71%) 6 (29%)
Gender, M:F 8:7 5:1 0.2 ‡ .3
Age, years 64 ± 16 67 ± 20 0.73 0.66
Height, cm 166.5 ± 8 169 ± 6.7 0.56 0.56
Weight, kg 79.1 ± 20.3 81.5 ± 14.4 0.79 0.95
BSA, m
2 1.86 ± 0.27 1.93 ± 0.2 0.56 0.74
Cardiac disease, n (%) 5 (24%) 4 (19%) 0.18 ‡ 0.17
APACHE III score (Day 1 ICU) 78.5 ± 24.9 84 ± 22.7 0.65 0.65
SOFA score (Day 1 ICU) 10.3 ± 2.6 12.3 ± 2.7 0.15 0.19
Study day
Time from onset of septic shock, days 2 ± 0.8 1.7 ± 0.5 0.34 0.3
APACHE III score 80.8 ± 33.2 88.2 ± 19.1 0.62 0.77
SOFA score 10.6 ± 3.6 13.3 ± 3.2 0.14 0.23
Mechanical ventilation, n (%) 10 (48%) 6 (29%) 0.15 ‡ 0.38
Clinical monitoring
HR, beats/min 87 ± 15 85 ± 10 0.77 0.7
SBP, mmHg 115 ± 16 109 ± 14 0.39 0.32
DBP, mmHg 54 ± 7 48 ± 9 0.21 0.16
MAP, mmHg 72 ± 8 68 ± 10 0.38 0.3
CVP, mmHg 13.8 ± 3 14.5 ± 6 0.72 0.63
Fluid and vasopressor management
Fluid balance, mL 1375 ± 1679 2792 ± 2009 0.11 0.08
Noradrenaline dose, μg/kg/min 0.115 ± 0.123 0.147 ± 0.111 0.58 0.47
Echocardiography
LA area, cm
2 22.49 ± 5.1 24.28 ± 4.45 0.46 0.35
LVEDVI, mL/m
2 61.2 ± 19.6 83 ± 26.6 0.08 0.14
LVESVI, mL/m
2 36 ± 20 43 ± 12 0.52 0.66
SVI, mL/m
2 25.1 ± 10.3 30.2 ± 22.8 0.62 † 0.62
EF, % 43 ± 15 43 ± 14 0.91 0.84
OTD, cm 2.054 ± 0.243 2.23 ± 0.17 0.13 0.17
VTI 19.63 ± 4.54 17.42 ± 6.71 0.41 0.4
Vpeak 1.084 ± 0.203 0.914 ± 0.297 0.16 0.1
CI, L/min/m
2 3.13 ± 0.96 3.18 ± 1.76 0.93 0.98
E, m/s 0.89 ± 0.24 1.04 ± 0.33 0.27 0.24
DT, s 0.215 ± 0.055 0.168 ± 0.032 0.07 0.07
E A fusion, n (%) 2 (9.5%) 2 (9.5%) 0.32 ‡ 0.4
A, m/s 0.6 ± 0.18 0.73 ± 0.33 0.32 0.3
E/A 1.7 ± 1.2 1.5 ± 0.6 0.75 0.7
e’, cm/s 10.4 ± 3.4 6.8 ± 1.9 0.025 0.04
a’, cm/s 9.9 ± 3.4 9.9 ± 3.2 0.99 0.96
e’a’ fusion, n (%) 1 (5%) 2 (9.5%) 0.18 ‡ 0.15
E/e’ 9.05 ± 2.75 15.32 ± 2.74 0.0002 0.005
s’, cm/s 13 ± 3.7 8.6 ± 4.1 0.03 0.048
Diastolic dysfunction, n (%) 8 (38%) 4 (19%) 0.66 ‡ 0.55
Biochemistry
BNP, ng/L 448 ± 607 1289 ± 1155 0.14 † 0.07 ¶
NTproBNP, ng/L 841 ± 818 1801 ± 1853 0.27 † 0.2 ¶
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of septic ICU patients. McLean and colleagues used E/e’
as an estimate of LV filling pressure in their prognostic
study of BNP in patients with severe sepsis and septic
shock [53]. They reported E/e’ to be non-significantly
lower in non-survivors (survivors 14.8 ± 7.4, non-survi-
vors 12.1 ± 4.6; P = 0.452). However, their study incor-
porated a number of patients with severe sepsis (lower
severity of illness compared with the current study), and
did not report fluid management, which is an important
determinant of survival in sepsis [54]. Bouhemad and
colleagues [55] used TDI to demonstrate isolated and
reversible impairment of ventricular relaxation in septic
shock patients with increased plasma troponin I concen-
tration but associations with mortality were not
assessed.
Cardiac biomarkers including BNP [23,24], NTproBNP
[25] and troponin [26] have been offered as potential
prognostic tools in the critically ill. Our study demon-
strates the superiority of TDI over these biomarkers.
This is potentially explained by the magnitude of poten-
tial confounders on plasma biomarker concentrations in
the critically ill [3]. Furthermore, TDI offers more direct
evaluation of myocardial function.
B-type natriuretic peptide
In general, BNP is a peptide hormone secreted by the
ventricular myocardial in response to wall stress [3]. Its
principal clinical use is the diagnosis of heart failure [56].
However, elevated BNP appears to lack validity as a bio-
marker of myocardial dysfunction in sepsis. Potential
explanations include inflammation [38], altered clearance
Figure 1 Receiver operating characteristic curve comparing E/e’ with BNP, and TnT as discriminators of hospital mortality. BNP, B-type
natriuretic peptide; E/e’, ratio of peak early diastolic transmitral flow velocity to peak early diastolic septal mitral annulus; TnT, Troponin T.
Table 3: Comparison of hospital survivors and nonsurvivors (Continued)
TnT, μg/L 0.114 ± 0.174 0.268 ± 0.251 0.12 0.03
CRP, mg/L 228 ± 85 207 ± 135 0.68 0.51
*Comparison performed using Student’s T test for independent groups (equal variance assumed) unless otherwise indicated. †Equal variances not assumed
(Levene’s test P < 0.05). ‡ Fisher’s exact test (2 tail). §Univariate Cox regression analysis of variables as predictors of hospital survival. ¶Variables log-transformed
prior to Cox regression analysis. A, peak active (late) diastolic transmitral flow velocity; a’, peak active (late) diastolic septal mitral annulus velocity; APACHE III,
Acute Physiology and Chronic Health Evaluation III; BNP, B-type natriuretic peptide; BSA, body surface area; CI, cardiac output indexed to body surface area; CRP,
C reactive protein; CVP, central venous pressure; DBP, diastolic blood pressure; DT, E wave deceleration time; E, peak early diastolic transmitral flow velocity;
e’, Peak early diastolic septal mitral annulus velocity; E/A, ratio of E to A; E/e’, patio of E to e’; EF, ejection fraction; F, female; HR, heart rate; LV, left ventricle or
ventricular; LVEDVI, left ventricular end-diastolic volume indexed to body surface area; LVESVI, left ventricular end-systolic volume indexed to body surface area;
M, male; MAP, mean arterial pressure; NTproBNP, N-terminal proBNP; OTD, LV outflow tract diameter; s’, peak systolic septal mitral annulus velocity; SBP, systolic
blood pressure; SD, standard deviation; SOFA, Sequential Organ Failure Assessment score; SVI, left ventricular stroke volume indexed to body surface area; TnT,
Troponin T; Vpeak, peak LV outflow tract velocity; VTI, LV outflow tract velocity time integral.
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tion [58], vasoactive and inotropic drugs [37], fluid man-
agement [36,59], and diastolic dysfunction [40].
On the basis of previous laboratory data [36] and our
own clinical research [60], we incorporated an auxiliary
aim of the current study of evaluating the potential
influence of fluid management on plasma BNP concen-
trations in septic shock. Also, the relation between dia-
stolic function and plasma BNP concentration had not
been evaluated in septic shock. We are the first to
demonstrate fluid balance and diastolic dysfunction as
independent predictors of plasma BNP concentration in
septic shock.
Limitations
In keeping with international guidelines for hemodynamic
monitoring in shock, our unit does not routinely use pul-
monary artery catheters [61], and LV filling pressure is not
pursued as a therapeutic target. Although incorporation of
pulmonary artery catheter data might have yielded inter-
esting comparisons, it was unnecessary to achieve or sta-
ted aims and might have impaired the feasibility of our
study. We propose that the resultant observational data
forms a robust reflection of clinical practice in the context
of contemporary sepsis management. Based on our find-
ings, additional research incorporating pulmonary artery
catheterization might now be justified.
We have reported TDI measurements taken at the
septal mitral annulus. This technique was based on
results reported by Ommen and colleagues demonstrat-
ing good prediction of LV end-diastolic pressure [33].
Although the feasibility of this approach in critical care
is appealing, the mean of measurements sampled around
the perimeter of the mitral valve would be less suscepti-
ble to regional wall motion abnormalities, if present [9].
The potential influence of mechanical ventilation, right
ventricular function and inotropes/vasopressors upon
tissue Doppler variables is unclear. Our observational
study has not been designed to clarify these potential
interactions but based on the current findings, further
research in these areas is justified.
In clinical studies, it is challenging to standardize data
collection at a fixed time from onset of sepsis. We studied
patients within 72 hours of development of septic shock
(admission to ICU or onset in ICU). The strength of this
design is that it potentially optimizes the comparison of
TDI with cardiac biomarkers, particularly BNP [23], as
predictors of outcome. Due to an inability to predict the
development of sepsis, we were unable to define the pre-
morbid diastolic function of the study participants.
Potential clinical significance and directions for future
research
The findings of this study are of potential clinical
importance. First, TDI might prove useful in risk strati-
fication. This may help identify septic shock patients
requiring more intensive therapy based upon their dia-
stolic performance. Secondly, the association between
diastolic dysfunction and mortality might offer a novel
therapeutic target. Further research incorporating thera-
pies targeted toward improved cardiac relaxation (lusi-
tropy) must be pursued.
Figure 2 Kaplan Meier plot of association between E/e’ and hospital survival. Cases are censored at hospital discharge. E/e’, ratio of peak
early diastolic transmitral flow velocity to peak early diastolic septal mitral annulus.
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In this preliminary study, we have found that after
adjustment for severity of illness, cardiac disease, fluid
management and grade of diastolic dysfunction, E/e’ is
an independent predictor of hospital survival in septic
shock patients. In addition, E/e’ offers better discrimina-
tion between hospital survivors and non-survivors than
cardiac biomarkers (BNP, NTproBNP, TnT). Fluid bal-
ance and diastolic dysfunction are independent predic-
tors of BNP concentration in septic shock.
Key messages
￿ E/e’ is an independent predictor of hospital survi-
val in septic shock patients.
￿ E/e’ offers better discrimination between hospital
survivors and non-survivors than cardiac biomarkers
(BNP, NTproBNP, TnT).
￿ Fluid balance and diastolic dysfunction are inde-
pendent predictors of BNP concentration in septic
shock.
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